Articles related to SGLT2 INHIBITORS

Large-scale propensity-matched analysis reveals differential cardiovascular outcomes between GLP-1 receptor agonists and SGLT-2 inhibitors in routine clinical practice.

SGLT2 inhibitors result in 300 calories of daily glucose elimination through urinary excretion, making dietary carbohydrate choices directly impact therapeutic effectiveness.

Post-trial analysis reveals a 13% relative reduction in cardiovascular death and kidney disease progression risk, though this benefit primarily manifests in the first 12 months after treatment discontinuation.

Recent research comparing SGLT2 inhibitors and dulaglutide in older patients with type 2 diabetes suggests a potential difference in dementia risk. The study estimated a risk ratio of 0.81 (CI, 0.56 to 1.16) for SGLT2 inhibitors compared to dulaglutide.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.